The US Food and Drug Administration (FDA) has approved applications for six new versions of heparin, an anticoagulant therapy that is also used to prevent clot formation in catheters.
Heparin, produced by Hospira, is available in numerous delivery systems for different modes of administration. The six new vial presentations approved by the FDA range in volume from 1ml to 30ml, and in concentration from 1,000 units per millilitre to 10,000 units per millilitre.
Hospira Specialty Pharmaceuticals vice-president Joshua Gordon said that with the addition of the new vials, Hospira now offers one of the broadest portfolios of heparin available on the US market.
“Hospira is committed to ensuring patient access to safe and effective supplies of heparin,” said Gordon.
Hospira is a global speciality pharmaceutical and medication delivery company.